Bayesian Capital Management’s Integra LifeSciences IART Stock Holding History

Bayesian Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-18,437	Closed	-$226K	–	656
2025 Q2	$226K	Buy	+18,437	New	+$268K	0.04%	436
2025 Q1	–	Sell	-32,500	Closed	-$737K	–	770
2024 Q4	$737K	Buy	+32,500	New	+$709K	0.09%	296
2024 Q1	–	Sell	-12,700	Closed	-$553K	–	927
2023 Q4	$553K	Buy	+12,700	New	+$500K	0.06%	359
2023 Q1	–	Sell	-31,758	Closed	-$1.78M	–	933
2022 Q4	$1.78M	Buy	+31,758	New	+$1.62M	0.26%	80
2022 Q3	–	Sell	-4,567	Closed	-$247K	–	847
2022 Q2	$247K	Buy	+4,567	New	+$274K	0.05%	543
2021 Q2	–	Sell	-2,954	Closed	-$204K	–	513
2021 Q1	$204K	Buy	+2,954	New	+$200K	0.05%	456
2017 Q1	–	Sell	-12,800	Closed	-$549K	–	536
2016 Q4	$549K	Buy	12,800 +1,212	+10%	+$49.3K	0.14%	284
2016 Q3	$478K	Buy	+11,588	New	+$485K	0.31%	113

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bayesian Capital Management's IART Position: Q3 2025 in Review

Bayesian Capital Management sold out of Integra LifeSciences (IART) in Q3 2025, closing a stake of 18,437 shares — an estimated $226K sold.

Bayesian Capital Management first reported a position in IART in Q3 2016 and held it in 8 quarters. The position peaked at $1.78M in Q4 2022. 207 funds tracked by Wall St. Rank hold IART as of Q3 2025.

Bayesian Capital Management reported no remaining Integra LifeSciences position as of Q3 2025 after selling out during the quarter.
Bayesian Capital Management sold 18,437 Integra LifeSciences shares in Q3 2025, an estimated $226K.
Bayesian Capital Management first reported a position in Integra LifeSciences in Q3 2016 and held it in 8 quarters.
Bayesian Capital Management's Integra LifeSciences position peaked at $1.78M in Q4 2022.
207 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2025.

Based on Bayesian Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.